Targeted Oncology

15/08/2025

The FDA fast-tracks HLD-0915, a novel therapy for metastatic castration-resistant prostate cancer, promising rapid development and potential breakthrough treatment. Read the full story →

FDA fast-tracks HLD-0915, a novel therapy for metastatic castration-resistant prostate cancer, promising rapid development and potential breakthrough treatment.

15/08/2025

In this episode of Targeted Treatment Tips, Dr Patrick Wen, Dana-Farber Cancer Institute, discusses some of the unique considerations clinicians should keep in mind when treating patients with dordaviprone (Modeyso), following its recent FDA approval in diffuse midline glioma.

14/08/2025

Colon cancer screening rates that are 20% higher. See how Mesmerize’s digital screens engage patients and deliver results where it counts.
Get Your No-Cost Screen: https://hubs.li/Q03xWnJ30

14/08/2025

In an exclusive interview, Jamie Jacobs, Phd, Mass General Hospital/Harvard Medical School, discusses how a digital app significantly enhances the quality of life for caregivers of stem cell transplant patients. Read more →

A digital app significantly enhances the quality of life for caregivers of stem cell transplant patients, reducing stress and improving coping abilities.

13/08/2025

Antonio Jimenez Jimenez, MD, discusses the NMDP ACCESS study exploring stem cell transplant access for diverse patients, improving outcomes with mismatched donors and innovative techniques. Read the exclusive interview →

A groundbreaking study enhances stem cell transplant access for diverse patients, improving outcomes with mismatched donors and innovative techniques.

12/08/2025

Final analysis of the TALAPRO-2 study combining talazoparib with enzalutamide significantly enhances survival rates in metastatic prostate cancer patients, regardless of genetic factors. Read more →

New research reveals that combining talazoparib with enzalutamide significantly enhances survival rates in metastatic prostate cancer patients, regardless of genetic factors.

12/08/2025

New trial results reveal that pembrolizumab and enfortumab vedotin significantly enhance survival rates for muscle-invasive bladder cancer patients ineligible for cisplatin. Read more→

New trial results reveal that pembrolizumab and enfortumab vedotin significantly enhance survival rates for muscle-invasive bladder cancer patients ineligible for cisplatin.

12/08/2025

Recognize a leader shaping the future of cancer care. Submit your Oncology Icons nomination by August 22 and give an outstanding community oncologist the recognition they deserve.

🏆 The winner is featured in Targeted Therapies in Oncology™ and offered exclusive opportunities to share their expertise.

Nominate Today https://hubs.li/Q03ClzpS0

11/08/2025

The FDA accepted a new drug application for vepdegestrant, a promising oral PROTAC developed by Arvinas and Pfizer, signaling potential breakthroughs in treatment. Read more →

The FDA accepts a new drug application for vepdegestrant, a promising oral PROTAC developed by Arvinas and Pfizer, signaling potential breakthroughs in treatment.

10/08/2025

Discover the latest breakthroughs in oncology, including FDA approvals and innovative therapies reshaping cancer treatment landscapes in this week's Targeted Pulse →

Discover the latest breakthroughs in oncology, including FDA approvals and innovative therapies reshaping cancer treatment landscapes.

08/08/2025

The FDA has granted accelerated approval to in HER2+ . Read about the breaking regulatory decision here →

Zongertinib gains FDA approval for advanced NSCLC with HER2 mutations, showcasing promising efficacy and safety in clinical trials.

08/08/2025

Despite its increased use, immunoglobulin replacement therapy does not lower the risk of serious infection in patients with chronic lymphocytic leukemia. Read the full story →

Despite its increased use, immunoglobulin replacement therapy does not lower the risk of serious infection in patients with chronic lymphocytic leukemia.